Research Use Only Is a Diagnostics Term
ON THIS PAGE
Key findings
- The only FDA guidance defining "research use only" labeling, issued November 25, 2013 by the Center for Devices and Radiological Health and the Center for Biologics Evaluation and Research, covers in vitro diagnostic products: reagents, instruments, and systems used to diagnose disease from a specimen taken from the human body. It does not mention research chemicals sold in a vial.
- This publication's ledger holds 126 supplier records, and three different searches over it on 2026-09-18 return three different numbers. 56 records carry the phrase "research use only" or the abbreviation RUO somewhere in the record. Two of those name 21 CFR 809.10(c) by number. One of those two names the regulation as the basis for a claim that its products are "not subject to FDA drug regulation."
- FDA's own guidance states that a label is not the end of the analysis: "mere placement of an RUO or IUO label on an IVD product does not render the device exempt from otherwise applicable clearance, approval, or other requirements," and intended use is read from the "totality of the circumstances," not the printed words.
- The FTC requires an advertiser to hold a reasonable basis for a claim before making it, defined as "objective evidence that supports the claim." The page states that requirement for an ad's claims generally and says the kind of evidence "depends on the claim," setting a higher bar for some categories, including health or safety claims, which must rest on "competent and reliable scientific evidence." The word purity appears nowhere on it. Reading a requirement stated that generally as reaching a statement about a product's regulatory status, the way it would reach a purity figure, is this publication's own step.
"Research use only" is the most common phrase on a peptide storefront, and it has exactly one FDA guidance document behind it. That document, "Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only," issued November 25, 2013 by the Center for Devices and Radiological Health and the Center for Biologics Evaluation and Research, opens by defining what it covers: in vitro diagnostic products, meaning "reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions... intended for use in the collection, preparation, and examination of specimens taken from the human body." A vial of a peptide is not that. The guidance never mentions one.
What 809.10(c) actually requires
Two storefronts in this publication's ledger cite 21 CFR 809.10(c) by number as the legal basis for their research-use-only labeling. The regulation is real and the citation is not wrong on its face, but it is a rule FDA issued under the Federal Food, Drug, and Cosmetic Act rather than a section of the Act itself, and what it names is a labeling requirement built for a different category of product. Section 809.10(c)(2)(i) sets the exact sentence a qualifying in vitro diagnostic product must carry: "For Research Use Only. Not for use in diagnostic procedures." The guidance is explicit about who that sentence is for, an IVD "in the laboratory research phase of development," not a bulk research chemical shipped for a lab to study on its own terms. Apex Lab Peptides' FAQ, read 2026-08-24, states as its own legal characterization that its compounds are "labeled 'For Research Use Only' in compliance with 21 CFR 809.10(c) and are therefore not subject to FDA drug regulation when sold and used strictly for research purposes." That is the vendor's claim, recorded as such. What this publication can add is only what the cited regulation itself covers on its face, which is diagnostic device labeling, and it is a reader's own judgment whether a research peptide fits inside that.
A label does not settle the question, even for the products it covers
The guidance's own point cuts against relying on the label at all, for the products it was written for. It states plainly: "Mere placement of an RUO or IUO label on an IVD product does not render the device exempt from otherwise applicable clearance, approval, or other requirements. FDA may determine that the device is intended for use in clinical diagnosis based on other evidence, including how the device is marketed." The standard the guidance sets is intended use, "determined by looking at the totality of the circumstances surrounding the distribution of the article," not the four words printed on a label. FDA lists what it looks at instead: labeling and advertising claims, product names and descriptors, instructions that go beyond research use, and solicitation of the customers a diagnostic device's real market would have. If FDA reads past its own label requirement to what a seller actually does, a label built for that framework was never going to be a stronger shield when borrowed for something the framework does not cover.
What the ledger shows sellers actually citing
The pattern in this ledger is a mix of framing choices, not one uniform claim. Legendary Peptides' footer disclaimer, read 2026-08-23, cites 21 CFR 809.10(c) alongside a separate statement that the company is neither a 503A compounding pharmacy nor a 503B outsourcing facility. That puts two sections of the Federal Food, Drug, and Cosmetic Act itself, 503A at 21 U.S.C. 353a and 503B at 353b, beside a regulation issued under that Act, in one line. 303 Peptides, read 2026-08-24, makes the same two disclaimers in its own longer wording, alongside an unusually detailed research-use-only paragraph. Full Scale Peptides, read 2026-08-25, runs a dedicated research-use-only page plus a block on its shop page carrying the line that FDA has not evaluated the product, and the regulation named on that dedicated page is not 809.10(c) at all. It is 21 C.F.R. 312.160, which sits in the investigational new drug rules rather than the diagnostic device ones. That section authorizes a person to ship a drug "intended solely for tests in vitro or in animals used only for laboratory research purposes" and sets its own label sentence for such a shipment: "CAUTION: Contains a new drug for investigational use only in laboratory research animals, or for tests in vitro. Not for use in humans." None of this is unusual phrasing for the category, and this publication takes no position on whether any of these businesses has read the guidance differently than it reads here. What the guidance itself says about its own scope is a fact a reader can check without this publication's help, at the document FDA published.
The claim about compliance is itself a claim
A sentence stating that a product "is therefore not subject to FDA drug regulation" is not a disclaimer. It is an affirmative statement about the law, made to a buyer deciding whether to trust a seller. The FTC's small-business advertising guidance states that standard for an ad's claims generally: "Before a company runs an ad, it has to have a 'reasonable basis' for the claims," and a reasonable basis "means objective evidence that supports the claim." The page does sort claims into categories, and where it does the effect is to raise the bar rather than lower it: health or safety claims, it says, "must be supported by 'competent and reliable scientific evidence.'" Reading a requirement stated that generally as reaching a claim about a product's regulatory status, the way it would reach a purity figure, is this publication's own step and not something the FTC page says. Take that step and a regulatory citation which, on its own published terms, governs diagnostic devices rather than research chemicals is not obviously the objective evidence that claim would need. It is the same test this publication ran on the certification badges a storefront prints, standard by standard: what the named document says it covers, checked against what is being sold. This publication is not a regulator and renders no finding on any specific seller's compliance. It can only point at the document being cited and let a reader compare what it says it covers against what is actually being sold.
Limitations and open questions
No FDA guidance defining "research use only" for a bulk research chemical, as opposed to a diagnostic device, appears to exist in the publicly searchable guidance library as of this writing, and this piece did not locate one. That gap is the reason enforcement practice, rather than a published definition, does the work of drawing the line for this category, and enforcement practice is documented case by case rather than stated as a general rule. A regulation on the drug side does exist and is quoted above, 21 C.F.R. 312.160, but it is a shipping authorization carrying its own label sentence rather than a definition of the phrase "research use only," and whether any particular vial falls inside it is not a question this publication answers. The three counts above are separate substring searches over this publication's own ledger, run 2026-09-18: 56 records matching "research use only" or "RUO" anywhere in the record, two matching the string "809.10", and one matching a "not subject to FDA drug regulation" phrasing. A looser or stricter search would return different numbers, and none of them is a claim about how many suppliers in this market overall use this framing. This piece takes no position on whether any named seller's use of the phrase is accurate, adequate, or misleading, only on what the one document that defines the phrase actually says it covers.
The phrase survives on a storefront because a shopper rarely opens the citation behind it. The document is public, it is short, and it says what it covers on its first page.
Sources
FDA, "Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only," Guidance for Industry and Food and Drug Administration Staff, Center for Devices and Radiological Health and Center for Biologics Evaluation and Research, whose cover page reads "Document issued on: November 25, 2013" (docket FDA-2011-D-0305, draft issued June 1, 2011), read in full 2026-09-18, for the IVD product definition, the required label text under 21 CFR 809.10(c)(2)(i), the "mere placement" and "totality of the circumstances" language, and the misbranding provisions it cites at 21 U.S.C. 352(a). The text of 21 C.F.R. 312.160, "Drugs for investigational use in laboratory research animals or in vitro tests," read 2026-09-18 in the government's own published edition of the Code of Federal Regulations, for the shipping authorization and its label sentence. The United States Code, read the same day, for the source credits that place section 503A of the Federal Food, Drug, and Cosmetic Act at 21 U.S.C. 353a and section 503B at 353b. FTC, "Advertising FAQ's: A Guide for Small Business," read 2026-09-18, for the reasonable-basis substantiation standard and the health or safety claim language quoted above. Supplier observations are this publication's own, from the dossier record in ledger/vendors.json: Apex Lab Peptides and 303 Peptides, both read 2026-08-24; Legendary Peptides, read 2026-08-23; and Full Scale Peptides, read 2026-08-25. Vendors are named here, never linked, per site policy.
Email updates
New articles and news by email, at most once a day or once a week, whichever you pick.
Respond to this analysis
Corrections, contradictions, and anything you have seen yourself. Responses are read and checked. Verified ones become entries in the ledger or corrections to this page. Nothing posts unverified, and no response is published with anything but the handle you type, or the display name of the account you sign in with. Reporting an error, or asking for this article to come down? Use the Report form below.
Report an error or request a takedown
Reports go to the site's administrators. Nothing is removed automatically.